INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 16,000 | -- | -- |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 24,000 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 5,149 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 4,800 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 94,851 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 100,000 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 45,200 | -- | -- |
| Feb 26, 2024 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Bona fide gift | 1,020 | -- | 50,999 |
| Nov 10, 2023 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Bona fide gift | 400 | -- | 52,700 |
| Nov 08, 2022 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Bona fide gift | 330 | -- | 52,465 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.